title: [New pharmacological treatment approaches to cardiogenic shock].
abstract: Cardiogenic shock after acute myocardial infarction continues to exhibit a high mortality rate. The prognosis can be improved with acute revascularization. Use of the intra-aortic balloon pump is also an established treatment concept. Administration of catecholamines should be limited as far as possible; monitoring hemodynamic parameters based on cardiac power output or cardiac power index can be very helpful. New treatment approaches such as the calcium sensitizer levosimendan, NO synthase inhibition, complement inhibition, or vasopressin therapy have not yet yielded convincing results. Future therapies will likely address the anti-inflammatory aspect of cardiogenic shock.
authors.affiliation: Universitätsklinik und Poliklinik für Innere Medizin III, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Strasse 40, Halle, Germany. michael.buerke@medizin.uni-halle.de
authors.forename: M
authors.initials: M
authors.lastname: Buerke
authors.forename: M
authors.initials: M
authors.lastname: Russ
authors.forename: K
authors.initials: K
authors.lastname: Werdan
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002395:Catecholamines / Q000009:adverse effects / Q000627:therapeutic use; D003182:Complement C5 / Q000037:antagonists & inhibitors; D051056:Complement Inactivating Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006835:Hydrazones / Q000009:adverse effects / Q000627:therapeutic use; D007423:Intra-Aortic Balloon Pumping; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality; D009204:Myocardial Revascularization; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012770:Shock, Cardiogenic / Q000188:drug therapy* / Q000401:mortality; D000077464:Simendan; D015996:Survival Rate; D014667:Vasopressins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002316:Cardiotonic Agents; D002395:Catecholamines; D003182:Complement C5; D051056:Complement Inactivating Agents; D006835:Hydrazones; D011724:Pyridazines; D014667:Vasopressins; D000077464:Simendan; D019001:Nitric Oxide Synthase